Literature DB >> 21377279

Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.

An Wouters1, Bea Pauwels, Hilde A J Lambrechts, Greet G O Pattyn, Johan Ides, Marc Baay, Paul Meijnders, Marc Peeters, Jan B Vermorken, Filip Lardon.   

Abstract

PURPOSE: Whereas radiosensitization by gemcitabine is well studied under normal oxygen conditions, little is known about its radiosensitizing potential under reduced oxygen conditions. Therefore, the present study evaluated the impact of anoxia on gemcitabine-mediated radiosensitization. METHODS AND MATERIALS: The clonogenic assay was performed in three isogenic A549 cell lines differing in p53 status (24 h, 0-15 nM gemcitabine, 0-8 Gy irradiation, normoxia vs. anoxia). Using radiosensitizing conditions, cells were collected for cell cycle analysis and apoptosis detection.
RESULTS: Whereas wild-type p53 A549-LXSN cells were more sensitive to radiation than p53-deficient A549-E6 cells, both cell lines showed similar radiosensitization by gemcitabine under normoxia and anoxia. Independent of p53 functionality, gemcitabine was able to overcome anoxia-induced G(0/1) arrest and established an (early) S phase block in normoxic and anoxic cells. The percentage early and late apoptotic/necrotic cells increased with the gemcitabine/radiation combination, with a significant difference between A549-LXSN and A549-E6.
CONCLUSIONS: This study is the first to show that gemcitabine retains its radiosensitizing potential under low oxygen conditions. Although radiosensitization was observed in both p53 wild-type and p53-deficient cells, p53 status might influence induction of apoptosis after gemcitabine/radiation treatment, whereas no effect on cell cycle progression was noticed.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21377279     DOI: 10.1016/j.ijrobp.2010.12.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Authors:  Marie Grøn Saelen; Anne Hansen Ree; Alexandr Kristian; Karianne Giller Fleten; Torbjørn Furre; Helga Helseth Hektoen; Kjersti Flatmark
Journal:  Radiat Oncol       Date:  2012-09-27       Impact factor: 3.481

2.  Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.

Authors:  Weiwei Xiao; Peter H Graham; Jingli Hao; Lei Chang; Jie Ni; Carl A Power; Qihan Dong; John H Kearsley; Yong Li
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

3.  Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.

Authors:  M Maftouh; A Avan; R Sciarrillo; C Granchi; L G Leon; R Rani; N Funel; K Smid; R Honeywell; U Boggi; F Minutolo; G J Peters; E Giovannetti
Journal:  Br J Cancer       Date:  2013-10-31       Impact factor: 7.640

4.  The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.

Authors:  An Wouters; Bea Pauwels; Natalie Burrows; Marc Baay; Vanessa Deschoolmeester; Trung Nghia Vu; Kris Laukens; Paul Meijnders; Dirk Van Gestel; Kaye J Williams; Danielle Van den Weyngaert; Jan B Vermorken; Patrick Pauwels; Marc Peeters; Filip Lardon
Journal:  BMC Cancer       Date:  2014-08-16       Impact factor: 4.430

5.  Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.

Authors:  Jolien Van den Bossche; Christophe Deben; Ken Op de Beeck; Vanessa Deschoolmeester; Christophe Hermans; Ines De Pauw; Julie Jacobs; Paul Van Schil; Jan Baptist Vermorken; Patrick Pauwels; Marc Peeters; Filip Lardon; An Wouters
Journal:  J Cancer       Date:  2017-05-12       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.